Paper26317305
Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.
Phillips T and 6 others. Appl Immunohistochem Mol Morphol, 2015. Cited by 155 papers, by iCite.
Cite this record
ConductScience Library. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Papers, record 26317305. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26317305
- Disease
- urinary bladder cancer87 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.
- PubMed
Connected records2
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Automation | Major topic |
| B7-H1 Antigen | Major topic |
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Lung Neoplasms | Major topic |
| Antibodies, Monoclonal | |
| Cell Line, Tumor | |
| Gene Knockdown Techniques | |
| Humans | |
| Immunohistochemistry |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04186013 | Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer | Results |
Source ClinicalTrials.gov
References15
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12091876 | Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. | Nat Med | 2002 | https://conductscience.org/library/papers/12091876 | PubMed |
| 2 | 12538684 | Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. | J Immunol | 2003 | https://conductscience.org/library/papers/12538684 | PubMed |
| 3 | 21179091 | A TALE nuclease architecture for efficient genome editing. | Nat Biotechnol | 2011 | https://conductscience.org/library/papers/21179091 | PubMed |
| 4 | 20373055 | High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. | Med Oncol | 2011 | https://conductscience.org/library/papers/20373055 | PubMed |
| 5 | 22658127 | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22658127 | PubMed |
| 6 | 23389362 | Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. | Tumori | 2012 | https://conductscience.org/library/papers/23389362 | PubMed |
| 7 | 22868219 | Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. | Clin Lung Cancer | 2013 | https://conductscience.org/library/papers/22868219 | PubMed |
| 8 | 24217091 | Programmed death ligand-1 expression in non-small cell lung cancer. | Lab Invest | 2014 | https://conductscience.org/library/papers/24217091 | PubMed |
| 9 | 24714771 | Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. | Clin Cancer Res | 2014 | https://conductscience.org/library/papers/24714771 | PubMed |
| 10 | 25399552 | Nivolumab in previously untreated melanoma without BRAF mutation. | N Engl J Med | 2015 | https://conductscience.org/library/papers/25399552 | PubMed |
| 11 | 25704439 | Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/25704439 | PubMed |
| 12 | 10581077 | B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. | Nat Med | 1999 | https://conductscience.org/library/papers/10581077 | PubMed |
| 13 | 11015443 | Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. | J Exp Med | 2000 | https://conductscience.org/library/papers/11015443 | PubMed |
| 14 | 25795410 | Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/25795410 | PubMed |
| 15 | 15297412 | B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. | Clin Cancer Res | 2004 | https://conductscience.org/library/papers/15297412 | PubMed |
Cited by97
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 155 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42568819 | Biomarkers for predicting and monitoring the efficacy of cancer vaccines. | Front Oncol | 2026 | https://conductscience.org/library/papers/42568819 | PubMed |
| 41702354 | Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung). | ESMO Open | 2026 | https://conductscience.org/library/papers/41702354 | PubMed |
| 41590351 | Machine Learning in Biomarker-Driven Precision Oncology: Automated Immunohistochemistry Scoring and Emerging Directions in Genitourinary Cancers. | Curr Oncol | 2026 | https://conductscience.org/library/papers/41590351 | PubMed |
| 41415556 | Unraveling the complexity of PD-L1 assays: a descriptive review of the methodology, scoring, and practical implications. | Front Oncol | 2025 | https://conductscience.org/library/papers/41415556 | PubMed |
| 40991883 | Clinical Interchangeability of PD-L1 Immunohistochemistry Assays in First-Line Non-Small Cell Lung Cancer Management With Cemiplimab. | JCO Precis Oncol | 2025 | https://conductscience.org/library/papers/40991883 | PubMed |
| 40775055 | Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial. | Nat Med | 2025 | https://conductscience.org/library/papers/40775055 | PubMed |
| 40514707 | Myomedin variants developed for in vitro PD-L1 diagnostics in tissue samples of non-small cell lung carcinoma patients. | J Transl Med | 2025 | https://conductscience.org/library/papers/40514707 | PubMed |
| 39074963 | Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies. | J Immunother Cancer | 2024 | https://conductscience.org/library/papers/39074963 | PubMed |
| 38927511 | Nearly Half of Patients with Anaplastic Thyroid Cancer May Be Amenable to Immunotherapy. | Biomedicines | 2024 | https://conductscience.org/library/papers/38927511 | PubMed |
| 38496691 | Immunotherapy for advanced non-small cell lung cancer with negative programmed death-ligand 1 expression: a literature review. | Transl Lung Cancer Res | 2024 | https://conductscience.org/library/papers/38496691 | PubMed |
| 37745839 | Role of immunotherapy in chondrosarcoma: A case report and review of the literature. | Ther Adv Med Oncol | 2023 | https://conductscience.org/library/papers/37745839 | PubMed |
| 37510761 | Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives. | J Clin Med | 2023 | https://conductscience.org/library/papers/37510761 | PubMed |
| 36892210 | Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patients. | Mol Oncol | 2023 | https://conductscience.org/library/papers/36892210 | PubMed |
| 36334214 | Predictive performance of PD-L1 tumor proportion score for nivolumab response evaluated using archived specimens in patients with non-small cell lung cancer experiencing a postoperative recurrence. | Invest New Drugs | 2023 | https://conductscience.org/library/papers/36334214 | PubMed |
| 36309362 | Clinicopathological and Prognostic Significance of Programmed Death Ligand-1 SP142 Expression in 132 Patients With Triple-negative Breast Cancer. | In Vivo | 2022 | https://conductscience.org/library/papers/36309362 | PubMed |
| 36190525 | A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/36190525 | PubMed |
| 36171566 | The expression profiles of CD47 in the tumor microenvironment of salivary gland cancers: a next step in histology-driven immunotherapy. | BMC Cancer | 2022 | https://conductscience.org/library/papers/36171566 | PubMed |
| 35840720 | Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab. | Mod Pathol | 2022 | https://conductscience.org/library/papers/35840720 | PubMed |
| 35327345 | Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches. | Biomedicines | 2022 | https://conductscience.org/library/papers/35327345 | PubMed |
| 35116387 | Clinicopathological implications of lncRNAs, immunotherapy and DNA methylation in lung squamous cell carcinoma: a narrative review. | Transl Cancer Res | 2021 | https://conductscience.org/library/papers/35116387 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| KRT18 | 3875 | PubTator's text mining | https://conductscience.org/library/genes/3875 | NCBI Gene |
| KRT8 | 3856 | PubTator's text mining | https://conductscience.org/library/genes/3856 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| ATEZOLIZUMAB | CHEMBL3707227 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL3707227 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26317305
GET https://conductscience.org/api/papers/v1/26317305/cited_by?page=2